Janney Montgomery Scott LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.

Quarter-by-quarter ownership
Janney Montgomery Scott LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$195
+3.2%
27,577
+2.6%
0.00%0.0%
Q2 2023$189
+5.0%
26,877
+24.3%
0.00%0.0%
Q1 2023$180
-25.9%
21,617
+2.1%
0.00%0.0%
Q4 2022$243
-99.9%
21,1670.0%0.00%0.0%
Q3 2022$267,000
+20.8%
21,1670.0%0.00%0.0%
Q2 2022$221,000
-46.0%
21,167
-15.9%
0.00%
-50.0%
Q1 2022$409,000
+17.2%
25,1670.0%0.00%
+100.0%
Q4 2021$349,000
-12.1%
25,167
-9.0%
0.00%
-50.0%
Q3 2021$397,000
-2.2%
27,650
+7.8%
0.00%0.0%
Q2 2021$406,000
+58.6%
25,650
+2.0%
0.00%
+100.0%
Q1 2021$256,000
+17.4%
25,150
-14.2%
0.00%0.0%
Q4 2020$218,000
+122.4%
29,300
+2.6%
0.00%0.0%
Q3 2020$98,000
-19.7%
28,550
+11.7%
0.00%0.0%
Q2 2020$122,000
+171.1%
25,550
+13.3%
0.00%
Q1 2020$45,000
-42.3%
22,550
-0.4%
0.00%
-100.0%
Q4 2019$78,000
+5.4%
22,635
-12.4%
0.00%0.0%
Q3 2019$74,000
-24.5%
25,8350.0%0.00%0.0%
Q2 2019$98,000
-55.0%
25,835
-3.7%
0.00%
-50.0%
Q1 2019$218,000
-0.5%
26,835
-1.1%
0.00%0.0%
Q4 2018$219,000
-2.2%
27,135
-7.5%
0.00%0.0%
Q3 2018$224,000
+33.3%
29,3350.0%0.00%0.0%
Q2 2018$168,000
+21.7%
29,335
+1.7%
0.00%
+100.0%
Q1 2018$138,000
-8.6%
28,835
-6.2%
0.00%
-50.0%
Q4 2017$151,000
-7.9%
30,735
-1.9%
0.00%0.0%
Q3 2017$164,000
-11.4%
31,335
-6.0%
0.00%0.0%
Q2 2017$185,000
-30.7%
33,335
+4.7%
0.00%
-50.0%
Q1 2017$267,000
+32.2%
31,8350.0%0.00%
+33.3%
Q4 2016$202,000
+38.4%
31,835
-4.1%
0.00%0.0%
Q3 2016$146,000
+100.0%
33,185
+29.2%
0.00%
+50.0%
Q1 2016$73,000
-72.8%
25,685
-1.0%
0.00%
-71.4%
Q4 2015$268,000
+24.1%
25,935
+36.6%
0.01%
+16.7%
Q3 2015$216,000
-99.9%
18,985
+10.8%
0.01%
+20.0%
Q2 2015$255,826,000
+211326.4%
17,135
+27.9%
0.01%
+150.0%
Q1 2015$121,000
-99.9%
13,400
+2.7%
0.00%
-33.3%
Q4 2014$158,688,000
+24.3%
13,0500.0%0.00%0.0%
Q3 2014$127,629,000
-23.3%
13,0500.0%0.00%
-25.0%
Q2 2014$166,388,000
+20.5%
13,0500.0%0.00%
+33.3%
Q1 2014$138,069,000
+61.5%
13,050
+16.0%
0.00%
+50.0%
Q4 2013$85,500,00011,2500.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders